Editorials
High cost of new drugs
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4136 (Published 27 July 2016) Cite this as: BMJ 2016;354:i4136
Related articles
- AnalysisBetting on hepatitis C: how financial speculation in drug development influences access to medicinesPublished: 27 July 2016; BMJ 354 doi:10.1136/bmj.i3718
- Feature Published: 27 July 2016; BMJ 354 doi:10.1136/bmj.i4117
- Letter Published: 23 August 2016; BMJ 354 doi:10.1136/bmj.i4524
- Letter Published: 05 October 2016; BMJ 355 doi:10.1136/bmj.i5314
- News Published: 10 October 2016; BMJ 355 doi:10.1136/bmj.i5493
- Analysis Published: 08 October 2020; BMJ 371 doi:10.1136/bmj.m3841
- Analysis Published: 27 June 2022; BMJ 377 doi:10.1136/bmj-2022-070876
See more
- Restricting direct GP referrals must not be a barrier to care, says RCGPBMJ September 21, 2023, 382 p2187; DOI: https://doi.org/10.1136/bmj.p2187
- BMA calls for investigation into debacle over covid and flu vaccinationsBMJ September 21, 2023, 382 p2184; DOI: https://doi.org/10.1136/bmj.p2184
- Understanding inequalities in breast cancer screening uptakeBMJ September 21, 2023, 382 p2084; DOI: https://doi.org/10.1136/bmj.p2084
- Suboptimal gestational weight gain and neonatal outcomes in low and middle income countries: individual participant data meta-analysisBMJ September 21, 2023, 382 e072249; DOI: https://doi.org/10.1136/bmj-2022-072249
- Tom Nolan’s research reviews—21 September 2023BMJ September 21, 2023, 382 p2125; DOI: https://doi.org/10.1136/bmj.p2125
Cited by...
- Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
- Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas
- Questions hang over European patent for hepatitis C drug after ruling
- Compulsory licences for direct acting antiviral drugs for hepatitis C
- Regulatory agencies should engage in drug pricing
- Patents: problem or panacea?